Search Within

Sarat Chandarlapaty

  1. "Komal Jhaveri"
Formats
  1. Journal Article (14)
  2. Meeting Abstract (12)
  3. Editorial (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (29)
  2. Breast Medicine Service (29)
  3. Department of Medicine (29)
  4. GSK Faculty (29)
  5. Human Oncology and Pathogenesis Program (29)
  6. Solid Tumor Oncology Division (29)

More Groups

People
  1. Komal Jhaveri (29)
  2. Shanu Modi (16)
  3. Pedram Razavi (15)
  4. Mark Robson (11)
  5. Maurizio Scaltriti (9)
  6. Jorge Reis-Filho (8)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (2)
  5. 2021 (4)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer Research (6)
  3. Cancer Discovery (2)
  4. Clinical Breast Cancer (2)
  5. npj Breast Cancer (2)
  6. Breast Cancer Research (1)

More Publications

Publishers
  1. American Association for Cancer Research (9)
  2. American Society of Clinical Oncology (7)
  3. Elsevier Inc. (4)
  4. Nature Publishing Group (2)
  5. American Association for the Advancement of Science (1)
  6. American Medical Association (1)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of dupilumab to manage antibody-drug conjugate-induced cutaneous toxicities
    Research Letter

    Nykaza, I.; Dusza, S. W.; Rosenberg, J. E.; Iyer, G.; Feld, E.; Chandarlapaty, S.; Jhaveri, K.; Lacuna, K.; Gajria, D.; Bielawa, M.; more...
    JAMA Dermatology (2025)

    Fulltext@MSK | Save
  • Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer
    Meeting Abstract

    Mai, N.; Liu, B.; Safonov, A.; Shen, S.; Zelizer, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.; Modi, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Journal Article

    Mai, N.; dos Anjos, C. H.; Razavi, P.; Safonov, A.; Patil, S.; Chen, Y.; Drago, J. Z.; Modi, S.; Bromberg, J. F.; Dang, C. T.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
    Meeting Abstract

    Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Meeting Abstract

    Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Accelerating drug development in breast cancer: New frontiers for ER inhibition
    Review

    Ferraro, E.; Walsh, E. M.; Tao, J. J.; Chandarlapaty, S.; Jhaveri, K.
    Cancer Treatment Reviews (2022)

    Fulltext@MSK | Save
  • The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation
    Journal Article

    Ladewig, E.; Michelini, F.; Jhaveri, K.; Castel, P.; Carmona, J.; Fairchild, L.; Zuniga, A. G.; Arruabarrena-Aristorena, A.; Cocco, E.; Blawski, R.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Drago, J. Z.; Shah, P. D.; Wang, R.; Pareja, F.; Ratzon, F.; Iasonos, A.; Patil, S.; Rosen, N.; Fornier, M. N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3Kα inhibitors
    Journal Article

    Cai, Y.; Xu, G.; Wu, F.; Michelini, F.; Chan, C.; Qu, X.; Selenica, P.; Ladewig, E.; Castel, P.; Cheng, Y.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save